Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bicycle Therapeutics (BCYC) EBIT Margin (2018 - 2025)

Historic EBIT Margin for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to 558.64%.

  • Bicycle Therapeutics' EBIT Margin rose 18272300.0% to 558.64% in Q3 2025 from the same period last year, while for Sep 2025 it was 5056.14%, marking a year-over-year increase of 82807600.0%. This contributed to the annual value of 17489.33% for FY2024, which is 139054500.0% down from last year.
  • Per Bicycle Therapeutics' latest filing, its EBIT Margin stood at 558.64% for Q3 2025, which was up 18272300.0% from 2965.82% recorded in Q2 2025.
  • Bicycle Therapeutics' EBIT Margin's 5-year high stood at 331.81% during Q4 2023, with a 5-year trough of 2965.82% in Q2 2025.
  • Over the past 5 years, Bicycle Therapeutics' median EBIT Margin value was 703.66% (recorded in 2025), while the average stood at 835.67%.
  • Its EBIT Margin has fluctuated over the past 5 years, first surged by 18695400bps in 2022, then plummeted by -24675100bps in 2025.
  • Quarter analysis of 5 years shows Bicycle Therapeutics' EBIT Margin stood at 2253.0% in 2021, then soared by 83bps to 383.46% in 2022, then soared by 187bps to 331.81% in 2023, then tumbled by -33bps to 222.82% in 2024, then plummeted by -351bps to 558.64% in 2025.
  • Its EBIT Margin stands at 558.64% for Q3 2025, versus 2965.82% for Q2 2025 and 703.66% for Q1 2025.